Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an
unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people
with type 2 diabetes who have not previously been treated with drug therapy to lower their
blood sugar.